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Background: The current treatment options for idiopathic membranous nephropathy (IMN) carry significant
toxicity. In this prospective, observational pilot study, we used single time infusion of bone marrow derived
autologous mononuclear cells (MNCs) in adult patients with treatment refractory IMN.
Methods: Twelve patients of biopsy proven IMN who had failed a cyclical 6-month regimen of steroid and
cyclophosphamide were enrolled in the study. Bone-marrow was harvested from the iliac crest and underwent
processing to isolate MNCs. Cells were counted and subjected to viability testing before being infused through a
peripheral vein on the same day. After the infusion, subjects were followed up monthly for the next six months.
Supportive treatment including angiotensin antagonists and statins was continued throughout the study period.
Result: The proteinuria, serum albumin and creatinine values at entry were 2.97 ± 0.6 gm/1.73 m2/d, 2.27 ± 1.1 gm/l
and 0.9 ± 0.8 mg/dl respectively. There was a reduction in proteinuria (p < 0.0001), and increase in serum albumin
(p = 0.001) at 1 month, with 64% of the subjects showing >50% reduction in proteinuria. However, the response
was ill sustained. At 6 months, only 2 patients had >50% reduction. Serum creatinine remained stable throughout
the study period. No infusion related side effects were noted.
Conclusion: Autologous mononuclear cell infusion leads to transitory reduction in proteinuria and improvement in
serum albumin in treatment refractory IMN. This effect, however, is transient. Whether this can be overcome by
repeated infusion of cultured mesenchymal cells needs to be investigated.Background
Idiopathic membranous nephropathy (IMN), the major
cause of nephrotic syndrome in adults, is an autoimmune
disorder. The recent discovery of phospholipase A2 recep-
tor (PLA2R) as the major target antigen and the associ-
ation of anti-PLA2R with disease activity has made the
role of specific dysregulation in the immune system
clearer [1]. IMN Patients typically present with nephrotic
syndrome; about a third remit spontaneously but of the
remainder, about 50% progress to ESRD by 10 years* Correspondence: vjha@pginephro.org
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reproduction in any medium, provided the orwithout treatment. Treatment involves the use of im-
munosuppressive drugs such as high dose-steroids and
alkylating agents or calcineurin inhibitors [2-4]. More re-
cently, the monoclonal anti-CD20 antibody rituximab has
shown promise [5]. Treatment is not successful in all
cases, associated with significant short and long-term side
effects and in the case of the last agent, expensive. Further,
identification of high-risk patients who would benefit from
such a therapy is at best empirical and approximate. Avail-
ability of relatively nontoxic therapy that could be applied
to most patients without fear of major adverse effects
holds a lot of attraction.
In recent years, the immunomodulatory property of
stem cells has received attention. The first evidence ofral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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benefit in refractory graft versus host disease following
hematopoietic stem cell transplantation [6]. The pro-
posed underlying mechanism is by elaboration of soluble
anti-inflammatory mediators as well as direct suppres-
sion of T-cells and dendritic cells [7]. There is encour-
aging progress in the use of these cells in animal models
of SLE, multiple sclerosis and Crohn’s disease [8]. Their
use in human subjects, however, is limited. This pilot
study was conducted as a proof-of-concept study as well
as to establish the safety profile of one-time infusion of
autologous mononuclear cells in adults with treatment
refractory IMN.Table 1 Patient characteristics
Parameter Value
Number of cases 11
Age (years) 29.36 ± 3.31
Gender ratio (M:F) 6:5
Duration of disease (months) 23 ± 4
Edema 11 (100)
Hypertension 10 (91)
Proteinuria (gm/day) 2.28 ± 0.4
Proteinuria (gm/1.73m2/day) 2.97 ± 0.6
Serum albumin (g/dl) 2.27 ± 1.1







ACEI only 4 (36)
ACEI + ARB 7 (64)
Diuretics 11 (100)
Statins 9 (82)Methods
Twelve patients were included in this pilot prospective ob-
servational study on the basis of following inclusion cri-
teria: age ≥ 16 years, biopsy proven IMN, already received
and failed a 6 months regimen of cyclical monthly steroid
and cyclophosphamide and/or CNI, off all immunosup-
pression for at least six months, nephrotic syndrome (de-
fined as proteinuria ≥3.5 g/1.73 m2/d or ≥2 g/d along with
serum albumin <2.5 g/dl, edema, and hyperlipidemia) and
on optimal therapy with angiotensin converting enzyme
inhibitors and/or angiotensin receptor blockers.
We excluded patients with systemic illness, malignancy,
diabetes, hepatitis B surface antigen positivity, or renal
vein thrombosis, pregnant patients, patient who failed to
give consent, cases with secondary membranous nephrop-
athy, those with nephrotic syndrome < 1 year, and patients
with eGFR <30 ml/min
Clearance was obtained from the Institute Ethics Com-
mittee and the Institute Committee on Stem Cell Research
and Therapy (Approval No IC-SCRT-18/2010/3576). All
subjects were explained about the exact nature of the in-
terventions, its potential benefits and harms and provided
written consent.
Mononuclear cells (MNCs) were processed from har-
vested bone marrow of individual patients. Bone marrow
aspirations were performed under sterile conditions under
local anesthesia from right posterior superior iliac spine.
Collected bone marrow was processed according to rec-
ommended level of sterility and biosafety precautions.
After processing, obtained cell counts as well as viability
were checked. About fifty μl of the final product was kept
for flowcytometric estimation of CD45, CD34 and CD105
positivity and rest of the product was diluted to a final vol-
ume of 10 ml. Cells were administered intravenously over
30 minutes. Patients were kept overnight in the hospital
and monitored for any delayed adverse reactions.
All subjects were followed up once a month for a
total period of six months. Supportive therapy including
ACEI ± ARBs, statins, antihypertensive and diureticswere continued. The primary endpoint was change in
proteinuria.
Statistical analysis was performed using IBM SPSS v
20.0 and GraphPad Prism v 4.0. Proteinuria, serum albu-
min and serum creatinine in the six consecutive monthly
visits were compared using non-parametric Friedman
test with Dunn’s post hoc analysis to identify the visits
between which there was a statistically significant differ-
ence. The proteinuria and serum albumin at the end of
first month were correlated with the infusate parameters
as well as other baseline values using Spearman bivariate
correlation test. A p value of less that 0.05 was consid-
ered statistically significantResults
A total of 12 subjects were recruited. One patient was
lost to follow up after the first visit following the proced-
ure, and 11 were available for analysis. Table 1 shows the
baseline characteristics of the subjects. Out of the 11 pa-
tients, there were six males, and the age range was 18–
45 years. All the patients were on ACE inhibitor or ACE
inhibitor with combination with ARBs. All the subjects
had already received and failed a six-month course of
cyclical monthly steroid and cyclophosphamide therapy.
Four patients had also received tacrolimus for 3–4 months.
Figure 1 Baseline and follow-up values of proteinuria.
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time of inclusion. Nine (75%) patients were receiving
HMG-CoA inhibitor therapy. Two had past episodes of
venous thrombosis, with one having had two episodes. Of
all the patients recruited, one did not satisfy the protein-
uria/serum albumin criteria but had experienced two epi-
sodes of venous thrombosis and was symptomatic and
hence was considered to be a candidate for treatment.
The volume of the bone marrow aspirate was 162.1 ±
25.1 ml. The number of the injected mononuclear cells
ranged between 8.51 × 107 and 2.32 × 108. The cells ex-
hibited high (96.27 ± 1.8%) viability. CD34 positivity was
seen in 0.38 ± 0.08% cells.
All subjects showed a reduction in proteinuria ran-
ging from 8-85% (Figure 1). The value decreased to
1.0 ± 0.61 g/day (p < 0.0001) at one month and 1.33 ±
0.7 g/day (p = 0.001) at 2 months. None of the sub-
jects underwent complete remission. The proteinuria
came back to 1.8 ± 1 g/day At 3 months and 2.15 ±
1.1 g/day at 6 months (p > 0.05). About 64% of the sub-
jects showed more than 50% decrease in proteinuria in
the first month, which decreased to 9% in the fifth month
of follow-up (Figure 2). This was associated with improve-
ment in serum albumin to the tune of 6-70% at 1 monthFigure 2 Proportion of subjects with greater than 50% decrease in pr(2.27 ± 0.57 d/dl vs 2.9 ± 0.8 g/dl, p = 0.001, Figure 3).
However, the response was ill sustained, the proteinuria
again increased and the serum albumin declined in major-
ity of the cases. There was no effect of this therapy on
serum creatinine (Figure 4).
The 24-hour urinary protein excretion at the first
month was not significantly correlated with any of the
infusate parameters (i.e. aspirate volume, number of cells,
percentage of MNCs or the viability of the cells), baseline
proteinuria or serum albumin values.
None of the patients experienced any infusion related
immediate adverse effects. Over six months of follow-
up, there was no report of any adverse events.
Discussion and conclusions
Cell-based therapies are being tried for several refractory
diseases, including immunologically mediated diseases
such as graft-versus-host disease, systemic lupus erythe-
matosus, rheumatoid arthritis and inflammatory bowel
disease, and for tolerance induction following kidney
transplantation [9-11]. Systemic administration of BM-
MNCs has been shown to be beneficial in coronary artery
disease, cardiomyopathy, diabetes mellitus and peripheral
vascular disease [12-14]. How exactly these cells exertoteinuria.
Figure 3 Baseline and follow-up values of serum albumin.
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but postulated mechanisms include paracrine and/or
immunomodulatory properties of progenitor cells. Sev-
eral cell types present in peripheral blood have immu-
nomodulatory properties, including the hematopoietic
and mesenchymal stem cells (MSC), dendritic cells and
various T-cell subsets.
IMN has all the attributes of the prototype auto-
immune disease, with the uniform presence of immune
deposits in the biopsy specimens, recent discovery of cir-
culating autoantibodies (anti-PLA2R) and response to
immunosuppressive therapies. Although the discovery of
anti-PLA2R antibody has been an interesting landmark
in understanding the disease pathogenesis, there has
been no major progress in the treatment of this entity
[1]. Even in the present time, treatment with steroid and
alkylating agents or calcineurin inhibitors remains the
gold standard. About 70% - 80% respond to such treat-
ment, but both regimes carry significant toxicities [15].
As only a subset of patients with IMN show progressive
renal dysfunction, ideally only these patients shouldFigure 4 Baseline and follow-up values of serum creatinine.receive therapy to alter disease course. Currently, how-
ever, there are no reliable markers to identify such pa-
tients at presentation. The current strategy is to wait
and reserve immunosuppressive treatment for patients
with persistent heavy proteinuria and/or declining renal
function. There is some evidence to suggest that earlier
treatment is associated with better response rates. In an
RCT where patients in control group were allowed to
cross over after 2 years, the remission rate in this group
was inferior compared to those in the intervention group
[3].
This preliminary study shows that use of autologous
bone marrow MNCs is safe and associated with transient
improvement in proteinuria in patients with IMN refrac-
tory to conventional treatment. Although the proteinuria
was relatively modest by western standards, all patients
had clinical manifestations of nephrotic state, most had
severe persistent hypoalbuminemia, edema, hyperlipid-
emia and/or complications related to nephrotic syn-
drome. We believe that the proteinuria might have
come down secondary to severe hypoalbuminemia. This
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jects. The edema decreased and serum albumin im-
proved after cell therapy, albeit transiently.
As most of the injected MNCs get trapped into pul-
monary microcirculation upon systemic injection [16], it
is unlikely that the administered cells would have actually
reached the kidneys in significant numbers and repaired
the damage by transdifferentiation. It is more likely that
cytokines secreted by the cells after injection might be re-
sponsible for any benefit. This could also explain the tran-
sient treatment effect.
While the improvement in proteinuria as well as
serum albumin one month post-procedure in a significant
proportion of patients was encouraging, the response was
ill sustained. This raises the question whether administra-
tion of a larger dose or repeated injections could provide a
more sustained benefit. Repeated bone marrow aspira-
tions, however, are not practical. Use of autologus bone-
marrow derived MSC, as is being currently tried for
immunomodulation in several diseases including for indu-
cing tolerance following kidney transplantation, might be
a more suitable option for repeated administration, since
these cells can be expanded and stored.
Our study provides the basis for further exploration of
cell-based therapy approaches in this condition. Possible
next steps could be use of cultured MSCs and/or cell
free extracts from supernatants of MSC culture. Since
levels of phospholipase A2 receptor reflect disease activ-
ity and have been shown to correlate with response, ser-
ial measurements of PLA2R levels would be useful in
attributing causality to response.
In conclusion, we show in this pilot study that use of
autologous bone marrow MNCs leads to transient de-
crease in proteinuria and improvement in hypoalbumin-
emia in IMN patients refractory to standard therapy.
MNC infusion is safe in this condition. More studies are
needed to explore the role of cell-based therapies in this
condition.
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